KYNB stock forecast, quote, news & analysis
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease... Show more
Kyntra Bio (KYNB) Stock Analysis: Clinical Catalysts Loom as Analyst Coverage Expands
Key Takeaways
- KYNB shares have traded in a tight range near $7.03, reflecting roughly flat performance over the past 30 days amid low-volume consolidation.
- Oppenheimer and Rodman & Renshaw initiated coverage in June–July 2026 with Outperform/Buy ratings and price targets of $35 and $30, respectively.
- The Phase 2 monotherapy trial of lead asset FG-3246 in metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling, with interim data expected in Q4 2026.
- A pivotal Phase 3 trial for roxadustat in lower-risk myelodysplastic syndromes (LR-MDS) is on track to initiate in the second half of 2026.
- Cash runway extends into 2028, supported by approximately $100.3 million in cash, equivalents, and investments as of March 31, 2026.
- Market capitalization hovers near $28.5 million, while the average analyst price target stands at approximately $39, signaling significant perceived upside contingent on clinical execution.
Current Market Snapshot
Kyntra Bio (KYNB) has traded in a narrow band between roughly $6.70 and $7.60 over the past 30 days, with low average daily volumes characteristic of a micro-cap biotechnology name. The stock closed at $7.03 on July 24, 2026, reflecting modest downward drift from the $7.24 level seen in late June. Broader biotech sentiment has been mixed, but KYNB's price action suggests a market in wait-and-see mode ahead of several binary clinical catalysts expected later this year. The recent initiation of coverage by two analyst firms — Oppenheimer (Outperform, $35 target) and Rodman & Renshaw (Buy, $30 target) — has drawn fresh attention to the company's pipeline and valuation disconnect.
Kyntra Bio (KYNB) Business Overview and Competitive Position
Kyntra Bio, formerly known as FibroGen, Inc., rebranded in January 2026 following a strategic transformation that included the sale of FibroGen China to AstraZeneca for approximately $220 million, repayment of its senior secured term loan, and a sharpened focus on oncology and rare disease. Headquartered in San Francisco, the company is advancing two primary programs: FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting CD46 for metastatic castration-resistant prostate cancer, and roxadustat, an oral HIF-PH inhibitor in late-stage development for anemia associated with lower-risk myelodysplastic syndromes. FG-3246 is the only CD46-directed ADC in clinical development and is paired with FG-3180, a companion PET imaging agent that may enable patient selection through biomarker stratification — a differentiating feature in the PSMA-dominated prostate cancer pipeline. Roxadustat is already approved in over 40 countries for anemia in chronic kidney disease and holds FDA Orphan Drug Designation for MDS.
Recent Developments Driving KYNB
Several developments have shaped investor sentiment over the past month. On July 7, Oppenheimer launched coverage with an Outperform rating and a $35 price target, citing optimism around FG-3246's unique mechanism and the potential for the upcoming Phase 2 interim readout to unlock value. Earlier, in mid-June, Rodman & Renshaw initiated with a Buy rating and a $30 target, highlighting the company's robust balance sheet and dual-asset pipeline. These analyst initiations followed the presentation of additional MATTERHORN Phase 3 data at the European Hematology Association (EHA) Congress, where roxadustat demonstrated clinically meaningful improvements in transfusion independence in LR-MDS patients regardless of ring sideroblast status. On the corporate front, the 2026 annual meeting on June 12 saw all proposals pass with overwhelming shareholder support. Meanwhile, CEO Thane Wettig made modest open-market purchases of 2,800 shares in May, a small but notable insider signal. The company's Q1 2026 results, reported in May, showed revenue growth to $3.7 million alongside reduced R&D and SG&A expenses, with management confirming the cash runway extends into 2028.
Trending AI Robots
For investors seeking data-driven approaches to navigate the market, Tickeron's Trending AI Robots page offers a curated view of top-performing AI-powered trading bots. Tickeron hosts hundreds of automated trading bots that analyze thousands of tickers across multiple strategies, timeframes, and performance metrics. The Trending AI Robots section highlights only the most relevant and consistently performing bots, helping traders quickly identify strategies that align with current market conditions. Whether focused on momentum, swing trading, or longer-term value plays, these bots provide actionable signals grounded in technical and fundamental analysis. Exploring the page can give traders a clearer picture of which AI-driven strategies are gaining traction right now.
2026 Outlook and What Investors Should Watch
The remainder of 2026 is poised to be a defining period for Kyntra Bio. The most critical catalyst is the interim analysis of the Phase 2 monotherapy trial for FG-3246 and FG-3180, expected in the fourth quarter. The trial design incorporates key learnings from earlier studies — including higher dosing, prophylactic G-CSF to mitigate neutropenia, and enrollment of earlier-line patients — with the goal of exceeding the 8.7-month median radiographic progression-free survival observed in Phase 1. Separately, the initiation of the pivotal Phase 3 trial for roxadustat in LR-MDS is anticipated in the second half of 2026, with the final protocol nearing completion following constructive FDA feedback in April. Investors should also monitor the company's cash burn trajectory, potential partnership discussions for roxadustat, and broader biotech sector sentiment. The Q2 2026 earnings report, expected around August 10, may provide updates on enrollment progress and trial timelines. While the analyst community sees substantial upside, execution risk remains a central consideration for clinical-stage biotechnology companies of this size.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
KYNB in upward trend: price may ascend as a result of having broken its lower Bollinger Band on July 20, 2026
KYNB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 32 cases where KYNB's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Bearish Trend Analysis
The 10-day RSI Indicator for KYNB moved out of overbought territory on July 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on July 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KYNB as a result. In of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for KYNB turned negative on July 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .
KYNB moved below its 50-day moving average on July 24, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for KYNB crossed bearishly below the 50-day moving average on July 30, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KYNB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (19.620). P/E Ratio (0.000) is within average values for comparable stocks, (38.277). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.532). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (3.660) is also within normal values, averaging (420.906).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. KYNB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KYNB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement